Miller ( MLR ) declares $0.21/share quarterly dividend , in line with previous. Forward yield 1.72% Payable June 8; for shareholders of record June 1; ex-div June 1. See MLR Dividend Scorecard, Yield Chart, & Dividend Growth. More on Miller Miller Industries: This Surprise Doesn't Change Things Miller Industries, Inc. (MLR) Q4 2025 Earnings Call Transcript Miller Industries, Inc. 2025 Q4 - Results...
Miller ( MLR ) declares $0.21/share quarterly dividend , in line with previous. Forward yield 1.72% Payable June 8; for shareholders of record June 1; ex-div June 1. See MLR Dividend Scorecard, Yield Chart, & Dividend Growth. More on Miller Miller Industries: This Surprise Doesn't Change Things Miller Industries, Inc. (MLR) Q4 2025 Earnings Call Transcript Miller Industries, Inc. 2025 Q4 - Results - Earnings Call Presentation Miller GAAP EPS of $0.05 misses by $0.22, revenue of $180.9M misses by $0.2M Miller Industries outlines $850M–$900M 2026 revenue target as military and European expansion drive growth
Kyowa Kirin press release ( KYKOF ): Q1 EPS (basic) of JPY 22.99. Revenue of JPY 118.46B (+13.1% Y/Y). More on Kyowa Kirin Co., Ltd. Kyowa Kirin Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for Kyowa Kirin Co., Ltd. Dividend scorecard for Kyowa Kirin Co., Ltd. Financial information for Kyowa Kirin Co., Ltd.
Kyowa Kirin press release ( KYKOF ): Q1 EPS (basic) of JPY 22.99. Revenue of JPY 118.46B (+13.1% Y/Y). More on Kyowa Kirin Co., Ltd. Kyowa Kirin Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for Kyowa Kirin Co., Ltd. Dividend scorecard for Kyowa Kirin Co., Ltd. Financial information for Kyowa Kirin Co., Ltd.
Earnings Call Insights: Revolution Medicines (RVMD) Q1 2026 Management view "This is a pivotal moment for our organization" following the RASolute 302 top-line readout, where "daraxonrasib monotherapy demonstrated an unprecedented improvement in overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer," according to (CEO, President & Chairman Mar...
Earnings Call Insights: Revolution Medicines (RVMD) Q1 2026 Management view "This is a pivotal moment for our organization" following the RASolute 302 top-line readout, where "daraxonrasib monotherapy demonstrated an unprecedented improvement in overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer," according to (CEO, President & Chairman Mark Goldsmith). Goldsmith said RASolute 302 showed daraxonrasib "meeting its primary and key secondary endpoints" with "statistically significant and clinically meaningful improvement in progression-free survival and overall survival compared to standard of care chemotherapy," adding that in the intent-to-treat population daraxonrasib drove a "60% reduction in the risk of death" and "a median overall survival exceeding 1 year." He also stated, "We intend to submit a new drug application to the U.S. Food and Drug Administration under the FDA Commissioner's National Priority Voucher Program." Goldsmith also highlighted access and disclosure milestones: "the FDA issued a safe-to-proceed letter allowing us to initiate an expanded access treatment protocol" and RASolute 302 "will be featured in the plenary session" at ASCO. Sandler said updated Phase I/II first-line metastatic pancreatic cancer data at AACR showed "encouraging preliminary durability," including 6-month Kaplan-Meier estimates of "71% and 83%" (PFS and OS) for daraxonrasib monotherapy and "84% and 90%" (PFS and OS) with gemcitabine plus nab-paclitaxel, adding, "The trial is enrolling globally" for Phase III RASolute 303. Sandler said the company "initiated RASolute 305" for zoldonrasib plus chemotherapy and "remain[s] on track to initiate RASolute 309" (zoldonrasib + daraxonrasib) "in the second half of the year." In NSCLC, he said the company is expanding RASolve 301 to "increase the statistical power" for overall survival and expects to "substantially complet[e] enrollment" this year. "We ended the first quarter o...
Barrett Business ( BBSI ) declares $0.08/share quarterly dividend , in line with previous. Forward yield 1.09% Payable June 5; for shareholders of record May 22; ex-div May 22. See BBSI Dividend Scorecard, Yield Chart, & Dividend Growth. More on Barrett Business Barrett Business Services, Inc. (BBSI) Q1 2026 Earnings Call Transcript Barrett Business Services, Inc. (BBSI) Q4 2025 Earnings Call Tran...
Barrett Business ( BBSI ) declares $0.08/share quarterly dividend , in line with previous. Forward yield 1.09% Payable June 5; for shareholders of record May 22; ex-div May 22. See BBSI Dividend Scorecard, Yield Chart, & Dividend Growth. More on Barrett Business Barrett Business Services, Inc. (BBSI) Q1 2026 Earnings Call Transcript Barrett Business Services, Inc. (BBSI) Q4 2025 Earnings Call Transcript BBSI reiterates 2026 outlook for 3%-5% gross billings growth while highlighting workers’ comp pricing momentum Barrett Business Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $307.01M beats by $2.07M Seeking Alpha’s Quant Rating on Barrett Business
(RTTNews) - Sinch AB (CLCMF, SINCH.ST), a communication platform, on Thursday reported a return to profitability in the first quarter despite a drop in revenue.
(RTTNews) - Sinch AB (CLCMF, SINCH.ST), a communication platform, on Thursday reported a return to profitability in the first quarter despite a drop in revenue.
Indonesia’s economy grew 5.6 per cent during the first quarter of 2026, its fastest pace in more than three years, but analysts warn that the coming months will pose significant tests for Southeast Asia’s biggest economy. Statistics body BPS attributed the growth to robust household consumption – which made up 54.36 per cent of gross domestic product and grew by 5.52 per cent year-on-year – and a ...
Indonesia’s economy grew 5.6 per cent during the first quarter of 2026, its fastest pace in more than three years, but analysts warn that the coming months will pose significant tests for Southeast Asia’s biggest economy. Statistics body BPS attributed the growth to robust household consumption – which made up 54.36 per cent of gross domestic product and grew by 5.52 per cent year-on-year – and a surge in government spending. Amalia Adininggar Widyasanti, head of BPS and deputy minister for...
On April 29th, Contemporary Amperex Intelligent Technology (Shanghai) Limited (CAIT), CATL's skateboard chassis arm, has entered into a strategic partnership with Turkish automotive brand Togg to jointly develop chassis platform for its new B-segment vehicle family, marking the first overseas passenger vehicle project for the platform.
On April 29th, Contemporary Amperex Intelligent Technology (Shanghai) Limited (CAIT), CATL's skateboard chassis arm, has entered into a strategic partnership with Turkish automotive brand Togg to jointly develop chassis platform for its new B-segment vehicle family, marking the first overseas passenger vehicle project for the platform.
A heavier representation by tech stocks and exposure to new industries has made South Korea’s index a worldbeater in 2026 while Canada has a greater representation by traditional industries like banking.
A heavier representation by tech stocks and exposure to new industries has made South Korea’s index a worldbeater in 2026 while Canada has a greater representation by traditional industries like banking.